← Eichor
Study identifier: NCT04467333 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Giessen Pulmonary Hypertension in Lung Cancer Registry

Condition: Pulmonary Hypertension Due to Lung Diseases and Hypoxia  ·  Sponsor: University of Giessen

PhaseN/A
Planned participants500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.

This description comes directly from the study's public registry record.

Talk to the study team

Bastian Eul, MD  ·  (+49) 0641/985-42371  ·  bastian.eul@innere.med.uni-giessen.de

Michael John Cekay, MD  ·  michael.cekay@innere.med.uni-giessen.de

Always discuss trial participation with your own doctor first.

Locations (1)

University hospital GiessenGiessen, Hesse, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04467333